Biomarkers Market 2020 Global Industry Analysis, Potential Growth, Key Players, Latest Trends (1)

1

• The global biomarkers market is set to gain
  traction from their increasing usage in a wide
  variety of applications, namely, drug discovery
  and development, safety assessment, and medicine.
  Besides, numerous biotech and pharmaceutical
  companies are persistently investing huge sums in
  the research and development activities. The
  increasing prevalence of cancer is also one of
  the crucial factors that would affect the market
  positively during the forecast period.
• The above information is given by Fortune
  Business Insights in a recent study, titled,
  Biomarkers Market Size, Share Industry
  Analysis, By Indication (Oncology, Cardiology,
  Neurology, and Others), By End User
  (Pharmaceutical Biotechnology Companies,
  Diagnostics Research Laboratories, Hospitals
  Specialty Clinics, and Others), and Regional
  Forecast, 2019-2026. The study further mentions
  that the biomarker market size was USD 39.10
  billion in 2018 and is projected to reach USD
  97.51 billion by 2026, thereby exhibiting a CAGR
  of 12.1 during the forecast period.
• Request a Sample Copy of the Research Report
• https//www.fortunebusinessinsights.com/enquiry/re
  quest-sample-pdf/biomarkers-market-102173
• Key Players Operating in The Biomarkers
  MarketInclude
• Key players are involved in mergers and
  acquisition to strengthen their market position.
  Owing to increasing competition frequent
  innovations are taking place in the market. Some
  of the companies operating the industry are
• Abbott
• RD System
• F. Hoffmann-La Roche Ltd.
• RD System
• Thermo Fisher Scientific
• Axon Medchem
• Bio-Rad Laboratories, Inc.
• BioVision Inc.

2

• Oncology Segment to Grow Steadily Backed by
  Rising Prevalence of Chronic Diseases
• In terms of indication, the market is grouped
  into oncology, cardiology, neurology and others.
  Out of these, the oncology segment dominated the
  market in 2018. This growth is attributable to
  the increasing cases of cancer. Growing demand
  for personalized medicine in diagnosis and
  treatment of cancer, along with increasing
  number of new biomarker based assays and tests
  being introduced by market players, is propelling
  the growth of oncology segment. Rising
  prevalence of neurological disorders and
  increasing investment by key market players in
  the development of neurology biomarkers are is
  one of the major factor anticipated to drive the
  growth of the segment at faster rate.
• Detailed Table of Content
• Introduction
• Research Scope
• Market Segmentation
• Research Methodology
• Definitions and Assumptions
• Executive Summary
• Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities
• Key Insights
• New Product Launches, by Key Market Players
• Prevalence by Disease Indication, By Key
  Countries/ Region, 2018
• Incidence of Cancer, By Key Countries/ Key
  Region,2018

3

• Robust research methodology
• Comprehensive reports
• Latest technological developments
• Value chain analysis
• Potential Biomarkers Marketopportunities
• Growth dynamics
• Quality assurance
• Post-sales support
• Regular report updates
• Reasons to Purchase this Report
• Comprehensive analysis of the Biomarkers
  Marketgrowth drivers, obstacles, opportunities,
  and other related challenges.
• Tracks the developments, such as new product
  launches, agreements, mergers and acquisitions,
  geographical expansions, and joint ventures.
• Identifies market restraints and boosters.
• Identifies all the possible segments present in
  the market to aid organizations in strategic
  business planning.
• KEY QUESTIONS ANSWERED

4
UK 44 2071 939123 APAC 91 744 740
1245 Email sales_at_fortunebusinessinsights.com
Linkedin Twitter BLogs